Compare

BeOne Medicines AG/$ONC

1D1W1M3M6MYTD1Y5YMAX

About BeOne Medicines AG

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Ticker
$ONC
Sector
Health
Primary listing
NASDAQ
Employees
12,000
Headquarters
Basel, Switzerland

ONC Metrics

BasicAdvanced
$46B
51.17
$7.81
0.63
-

What the Analysts think about ONC

Analyst ratings (Buy, Hold, Sell) for BeOne Medicines AG stock.
Analyst projections of the future price of BeOne Medicines AG stock.

Bulls say / Bears say

BRUKINSA remains a strong growth engine: global sales rose 34% in the third quarter, with U.S. sales topping $1 billion, and the FDA gave priority review to an application that could add first-line mantle cell lymphoma use. (SEC)
Profitability is scaling alongside sales. Third-quarter GAAP operating income rose 157% and free cash flow increased 34%, prompting BeOne to raise its 2026 revenue and operating-income guidance. (SEC)
BeOne is building growth beyond BRUKINSA: TEVIMBRA sales increased 28% in the quarter, and the FDA approved a TEVIMBRA-based regimen for first-line HER2-positive gastroesophageal cancer. Several solid-tumour programmes are also advancing towards pivotal trials. (BeOne Medicines, Business Wire)
The business remains concentrated in BRUKINSA, which accounted for roughly three-quarters of third-quarter revenue. U.S. sales also benefited from about $50 million of order timing and an extra shipping day, making that quarter’s growth somewhat flattered. (The Motley Fool)
Management expects higher Medicare Part D manufacturer liability to turn a modest 2026 pricing benefit into a flat-to-modest headwind in 2027, which could weigh on BRUKINSA economics. (The Motley Fool)
The Amgen-licensed portfolio faces potential sales pressure beyond 2026: BeOne flagged biosimilar competition for XGEVA and possible value-based purchasing inclusion for XGEVA and KYPROLIS. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

ONC Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

ONC Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing ONC

AllUSDEUR
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.